Technical Analysis for ELOX - Eloxx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 2.76 5.34% 0.14
ELOX closed up 5.34 percent on Thursday, April 15, 2021, on 63 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ELOX trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Stochastic Buy Signal Bullish 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Jack-in-the-Box Bearish Bearish Swing Setup 5.34%
Inside Day Range Contraction 5.34%
Wide Bands Range Expansion 5.34%
Down 3 Days in a Row Weakness 5.34%
Down 4 Days in a Row Weakness 5.34%
Older End-of-Day Signals for ELOX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% about 13 hours ago
Up 3% about 15 hours ago
Up 2% about 17 hours ago
Up 1% about 17 hours ago
60 Minute Opening Range Breakout 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Eloxx Pharmaceuticals, Inc. Description

Eloxx Pharmaceuticals, Inc. (ELOX) is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Clinical Development Rare Diseases Genetics Molecular Biology Gene Expression Genetic Disease Cystic Fibrosis Genetic Diseases Messenger RNA Molecular Genetics Rehovot Rare And Ultra Rare Diseases

Is ELOX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.77
52 Week Low 1.98
Average Volume 104,868
200-Day Moving Average 3.27
50-Day Moving Average 3.61
20-Day Moving Average 3.16
10-Day Moving Average 2.99
Average True Range 0.32
ADX 15.51
+DI 15.52
-DI 22.50
Chandelier Exit (Long, 3 ATRs ) 3.15
Chandelier Exit (Short, 3 ATRs ) 3.51
Upper Bollinger Band 3.78
Lower Bollinger Band 2.54
Percent B (%b) 0.18
BandWidth 38.99
MACD Line -0.26
MACD Signal Line -0.21
MACD Histogram -0.0425
Fundamentals Value
Market Cap 110.82 Million
Num Shares 40.2 Million
EPS -1.45
Price-to-Earnings (P/E) Ratio -1.91
Price-to-Sales 0.00
Price-to-Book 7.96
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.09
Resistance 3 (R3) 3.08 2.95 3.04
Resistance 2 (R2) 2.95 2.87 2.96 3.02
Resistance 1 (R1) 2.86 2.82 2.91 2.87 3.00
Pivot Point 2.73 2.73 2.76 2.74 2.73
Support 1 (S1) 2.64 2.65 2.69 2.65 2.52
Support 2 (S2) 2.51 2.60 2.52 2.50
Support 3 (S3) 2.42 2.51 2.49
Support 4 (S4) 2.43